Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
2.
J Allergy Clin Immunol Pract ; 10(12): 3131-3138, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-36174919

RESUMEN

Natural products are a category of Complementary and Alternative Medicine that includes medicinal plants, vitamins, and dietary supplements. These products are often utilized by patients with allergies in conjunction with, or as an alternative to, their conventional medical therapies. Despite the wide use of these modalities, many clinicians often have limited knowledge and training in their use. It is important for health care providers to know the safety and risks of these products that their patients may use. This Clinical Commentary reviews the side effects and adverse reactions of several natural products commonly used by patients with allergies and gives an overview of the U.S. Food and Drug Administration requirements for manufacturing, advertising and distribution.


Asunto(s)
Productos Biológicos , Terapias Complementarias , Plantas Medicinales , Humanos , Productos Biológicos/efectos adversos , Plantas Medicinales/efectos adversos , Vitaminas/uso terapéutico , Suplementos Dietéticos/efectos adversos
3.
Gastrointest Endosc ; 70(3): 488-94, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19555941

RESUMEN

BACKGROUND: Because of greater recognition and improved imaging capabilities, intraductal papillary mucinous neoplasms (IPMNs) are being diagnosed with increasing frequency. IPMNs of the main pancreatic duct cause symptoms and lead to pancreatitis. Side-branch (SB) IPMNs are thought to cause symptoms less frequently, and their association with pancreatitis is not well defined. OBJECTIVE: Our purpose was to ascertain whether an association exists between SB-IPMN and pancreatitis. DESIGN: Single-center, retrospective study. SETTING: Academic medical center. PATIENTS: A total of 305 patients underwent EUS examinations between October 2002 and October 2006 for pancreatic cystic lesions. MAIN OUTCOME MEASUREMENT: The main outcome measure was the frequency of acute or chronic pancreatitis that was not procedurally related. RESULTS: Thirty-two patients had SB-IPMNs, and 11 (34%) had pancreatitis. Three patients reported a single episode, and 8 patients reported having recurrent episodes of pancreatitis. Overall, 17 (53%) patients had symptoms possibly attributable to SB-IPMN. Female sex (73% vs 38%) and multiple pancreatic lesions (54% vs 24%) were more commonly seen in those with pancreatitis, but were not statistically significant factors. Larger cyst size or cyst fluid marker levels did not appear associated with pancreatitis occurrence. EUS-FNA demonstrated communication with the pancreatic duct in 94% and thick, mucinous fluid in 84%. LIMITATIONS: Single-center, retrospective study. CONCLUSIONS: Pancreatitis was frequently associated with the presence of SB-IPMNs in our referral practice. SB-IPMNs should be considered in the differential diagnosis of patients with recurrent pancreatitis with cystic lesions seen on imaging studies. EUS-FNA was the most useful modality in helping to differentiate SB-IPMNs from other lesions.


Asunto(s)
Carcinoma Ductal Pancreático/diagnóstico por imagen , Carcinoma Ductal Pancreático/epidemiología , Neoplasias Pancreáticas/diagnóstico por imagen , Neoplasias Pancreáticas/epidemiología , Pancreatitis Aguda Necrotizante/diagnóstico por imagen , Pancreatitis Aguda Necrotizante/epidemiología , Centros Médicos Académicos , Adenocarcinoma Mucinoso/diagnóstico por imagen , Adenocarcinoma Mucinoso/epidemiología , Adenocarcinoma Mucinoso/patología , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Biopsia con Aguja Fina , Carcinoma Ductal Pancreático/patología , Estudios de Cohortes , Comorbilidad , Diagnóstico Diferencial , Endosonografía , Femenino , Humanos , Inmunohistoquímica , Incidencia , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/patología , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Distribución por Sexo , Análisis de Supervivencia
4.
Pediatrics ; 126(4): e851-8, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20876178

RESUMEN

OBJECTIVE: Our aim was to estimate the cumulative effective doses (CEDs) from radiologic procedures for a cohort of pediatric oncology patients. METHODS: A retrospective cohort study of the imaging histories of 150 pediatric oncology patients (30 each in 5 subgroups, that is, leukemia, lymphomas, brain tumors, neuroblastomas, and assorted solid tumors) for 5 years after diagnosis was performed. All procedures involving ionizing radiation were recorded, including radiography, computed tomography (CT), nuclear medicine (NM) studies, fluoroscopy, and interventional procedures. CED estimates were calculated. RESULTS: Individual CED estimates ranged from <1 mSv to 642 mSv, with a median of 61 mSv. CT and NM were the greatest contributors; CT constituted 30% of procedures but 52% of the total CED, and NM constituted 20% and 46%, respectively. There was considerable variability between tumor subgroups. CED estimates were highest in the neuroblastoma (median: 213 mSv [range: 36-489 mSv]) and lymphoma (median: 191 mSv [range: 10-642 mSv]) groups and lowest in the leukemia group (median: 5 mSv [range: 0.2-57 mSv]). CONCLUSIONS: CEDs from diagnostic and interventional imaging for pediatric oncology patients vary considerably according to diagnoses, individual clinical courses, and imaging modalities used. Increased awareness may promote strategies to reduce the radiation burden to this population.


Asunto(s)
Neoplasias/diagnóstico por imagen , Neoplasias/radioterapia , Dosis de Radiación , Adolescente , Niño , Preescolar , Femenino , Fluoroscopía , Humanos , Lactante , Recién Nacido , Leucemia/diagnóstico por imagen , Leucemia/radioterapia , Linfoma/diagnóstico por imagen , Linfoma/radioterapia , Masculino , Neuroblastoma/diagnóstico por imagen , Neuroblastoma/radioterapia , Radiografía Intervencional , Cintigrafía , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA